Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1–7)

Therapeutic Advances in Cardiovascular Disease

Volumn 5, Issue 6, 2011, Pages 297-304

  Igase, Michiya ^a   Yokoyama, Hiroshi ^b   Ferrario, Carlos M ^c  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Tagawa Municipal Hospital   (Japan)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

angiotensin (1 7); angiotensin II; angiotensin receptor blockers; angiotensin receptors; angiotensin converting enzyme 2; atenolol; blood pressure; glomerulosclerosis

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; ATENOLOL; OLMESARTAN;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; BIOACCUMULATION; BLOOD PRESSURE REGULATION; BRADYCARDIA; CONTROLLED STUDY; CORRELATION ANALYSIS; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HORMONE ACTION; HYPERTENSION; HYPERTENSIVE NEPHROPATHY; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PERIVASCULAR COLLAGEN DEPOSITION; RENAL PROTECTION; REVIEW; SCORING SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANGIOTENSIN I; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ATENOLOL; BLOOD PRESSURE; HEMODYNAMICS; HYPERTENSION; IMIDAZOLES; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; PEPTIDE FRAGMENTS; RATS; RATS, INBRED SHR; SCLEROSIS; TETRAZOLES;

EID: 83655190369     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944711429343     Document Type: Article

References (25)

1. Batlle D. Soler M.J. Wysocki J. (2008) New aspects of the renin–angiotensin system: angiotensin-converting enzyme 2 - a potential target for treatment of hypertension and diabetic nephropathy. Curr Opin Nephrol Hypertens 17: 250–257.
2. Boffa J.J. Lu Y. Placier S. Stefanski A. Dussaule J.C. Chatziantoniou C. (2003) Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 14: 1132–1144.
3. DelliPizzi A.M. Hilchey S.D. Bell-Quilley C.P. (1994) Natriuretic action of angiotensin(1-7). Br J Pharmacol 111: 1–3.
4. Eijkelkamp W.B. Zhang Z. Brenner B.M. Cooper M.E. Devereux R.B. Dahlof B. et al. (2007) Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. J Hypertens 25: 871–876.
5. Ferrario C.M. Ahmad S. Joyner J. Varagic J. (2010) Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7). Adv Pharmacol 59: 197–233.
6. Ferrario C.M. Averill D.B. Brosnihan K.B. Chappell M.C. Iskandar S.S. Dean R.H. et al. (2002) Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat. Kidney Int 62: 1349–1357.
7. Ferrario C.M. Jessup J. Chappell M.C. Averill D.B. Brosnihan K.B. Tallant E.A. et al. (2005 a) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605–2610.
8. Ferrario C.M. Jessup J. Gallagher P.E. Averill D.B. Brosnihan K.B. Ann T.E. et al. (2005 b) Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 68: 2189–2196.
9. Ferrario C.M. Trask A.J. Jessup J.A. (2005 c) Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289: H2281–H2290.
10. Ferrario C.M. Varagic J. (2010) The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am J Physiol Renal Physiol 298: F1297–F1305.
11. Garcia N.H. Garvin J.L. (1994) Angiotensin 1-7 has a biphasic effect on fluid absorption in the proximal straight tubule. J Am Soc Nephrol 5: 1133–1138.
12. Handa R.K. Ferrario C.M. Strandhoy J.W. (1996) Renal actions of angiotensin-(1-7): in vivo and in vitro studies. Am J Physiol 270: F141–F147.
13. Hilchey S.D. Bell-Quilley C.P. (1995) Association between the natriuretic action of angiotensin-(1-7) and selective stimulation of renal prostaglandin I 2 release. Hypertension 25: 1238–1244.
14. Hill G.S. (2008) Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens 17: 266–270.
15. Igase M. Strawn W.B. Gallagher P.E. Geary R.L. Ferrario C.M. (2005) Angiotensin II AT 1 receptors regulate ACE 2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289: H1013–H1019.
16. Li J.S. Schiffrin E.L. (1996) Effect of calcium channel blockade or angiotensin-converting enzyme inhibition on structure of coronary, renal, and other small arteries in spontaneously hypertensive rats. J Cardiovasc Pharmacol 28: 68–74.
17. Morel-Maroger S.L. Killen P.D. Chi E. Striker G.E. (1984) The composition of glomerulosclerosis. I. Studies in focal sclerosis, crescentic glomerulonephritis, and membranoproliferative glomerulonephritis. Lab Invest 51: 181–192.
18. Oudit G.Y. Herzenberg A.M. Kassiri Z. Wong D. Reich H. Khokha R. et al. (2006) Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 168: 1808–1820.
19. Ren Y. Garvin J.L. Carretero O.A. (2002) Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension 39: 799–802.
20. Shao Y. He M. Zhou L. Yao T. Huang Y. Lu L.M. et al. (2008) Chronic angiotensin (1-7) injection accelerates STZ-induced diabetic renal injury. Acta Pharmacol Sin 29: 829–837.
21. Tikellis C. Johnston C.I. Forbes J.M. Burns W.C. Burrell L.M. Risvanis J. et al. (2003) Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41: 392–397.
22. Wong D.W. Oudit G.Y. Reich H. Kassiri Z. Zhou J. Liu Q.C. et al. (2007) Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 171: 438–451.
23. Yiu W.H. Pan C.J. Ruef R.A. Peng W.T. Starost M.F. Mansfield B.C. et al. (2008) Angiotensin mediates renal fibrosis in the nephropathy of glycogen storage disease type Ia. Kidney Int 73: 716–723.
24. Yokoyama H. Averill D.B. Brosnihan K.B. Smith R.D. Schiffrin E.L. Ferrario C.M. (2005) Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. Am J Hypertens 18: 922–929.
25. Zhao W. Chen S.S. Chen Y. Ahokas R.A. Sun Y. (2008) Kidney fibrosis in hypertensive rats: role of oxidative stress. Am J Nephrol 28: 548–554.